Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor

Details for Australian Patent Application No. 2005237254 (hide)

Owner Novartis AG

Inventors Lake, Philip

Agent Davies Collison Cave

Pub. Number AU-B-2005237254

PCT Pub. Number WO2005/105146

Priority 60/590,061 21.07.04 US; 60/567,677 03.05.04 US

Filing date 2 May 2005

Wipo publication date 10 November 2005

Acceptance publication date 4 February 2010

International Classifications

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

Event Publications

9 November 2006 PCT application entered the National Phase

  PCT publication WO2005/105146 Priority application(s): WO2005/105146

4 February 2010 Application Accepted

  Published as AU-B-2005237254

3 June 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005237255-Management of breakthrough bleeding in extended hormonal contraceptive regimens

2005237251-Formulation comprising histone deacetylase inhibitors